Recent data suggests that retatrutide, a dual-action medication, might represent a significant step in size reduction . This drug combines the effects of a GLP-1 analog and a GIP receptor , seemingly offering a enhanced impact than current therapies . Patient research have demonstrated encouraging findings , including significant reductions in weig